Autolus Therapeutics (NASDAQ:AUTL) Trading 6.8% Higher – Here’s Why

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price was up 6.8% during trading on Wednesday . The stock traded as high as $3.31 and last traded at $3.31. Approximately 490,371 shares traded hands during trading, a decline of 66% from the average daily volume of 1,461,731 shares. The stock had previously closed at $3.10.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on AUTL shares. Needham & Company LLC restated a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a research report on Monday, November 11th. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Finally, Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $10.15.

Autolus Therapeutics Stock Up 5.7 %

The stock has a market capitalization of $870.13 million, a price-to-earnings ratio of -2.79 and a beta of 2.04. The company has a 50 day simple moving average of $3.75 and a 200-day simple moving average of $3.93.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the company earned ($0.26) EPS. As a group, sell-side analysts anticipate that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its stake in Autolus Therapeutics by 82.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after acquiring an additional 2,487,778 shares during the period. Bayesian Capital Management LP bought a new position in Autolus Therapeutics in the 1st quarter valued at about $100,000. B. Riley Wealth Advisors Inc. purchased a new position in shares of Autolus Therapeutics during the first quarter valued at approximately $108,000. Cetera Advisors LLC bought a new stake in shares of Autolus Therapeutics in the 1st quarter worth $839,000. Finally, SG Americas Securities LLC increased its stake in shares of Autolus Therapeutics by 853.2% during the 2nd quarter. SG Americas Securities LLC now owns 189,240 shares of the company’s stock worth $659,000 after purchasing an additional 169,387 shares during the last quarter. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.